Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothe...
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluo...
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
Irinotecan or Fluorouracil Plus Leucovorin in Treating Patients With Previously Treated Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 19
- Registration Number
- NCT00016952
- Locations
- 🇨🇦
Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
🇺🇸Siouxland Hematology-Oncology, Sioux City, Iowa, United States
🇺🇸CCOP - Wichita, Wichita, Kansas, United States
Combination Chemotherapy in Treating Patients With Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 90
- Registration Number
- NCT00021073
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2021-09-09
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 46
- Registration Number
- NCT00025285
- Locations
- 🇺🇸
CCOP - Upstate Carolina, Spartanburg, South Carolina, United States
🇺🇸Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States
🇺🇸CCOP - Central Illinois, Decatur, Illinois, United States
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-14
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 77
- Registration Number
- NCT00003955
- Locations
- 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Naval Medical Center, Portsmouth, Portsmouth, Virginia, United States
🇺🇸University of Connecticut Comprehensive Cancer Center at University of Connecticut Health Center, Farmington, Connecticut, United States
Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-05-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 560
- Registration Number
- NCT00005036
- Locations
- 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States
S0119: Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-15
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 85
- Registration Number
- NCT00030433
- Locations
- 🇺🇸
Veterans Affairs Medical Center - West Los Angeles, Los Angeles, California, United States
🇺🇸Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States
🇺🇸CCOP - Central Illinois, Decatur, Illinois, United States
Irinotecan in Treating Children With Refractory or Progressive Solid Tumors
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Texas Children's Cancer Center
- Registration Number
- NCT00016861
- Locations
- 🇺🇸
Texas Children's Cancer Center, Houston, Texas, United States
Floxuridine, Dexamethasone, and Irinotecan After Surgery in Treating Patients With Liver Metastases From Colorectal Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00003753
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00030862
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 77
- Registration Number
- NCT00042874
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.